Radioimmunotherapy study of 131 I-labeled Atezolizumab in preclinical models of colorectal cancer.

Linhan ZhangSheng ZhaoHuijie JiangRongjun ZhangMingyu ZhangWenbin PanZhongqi SunDandan WangJinping Li

Published in: EJNMMI research (2022)

I-Atezolizumab can be used as a CLI agent for screening PD-L1 expression levels. It may be used as a radioimmunotherapy drug target for PD- L1 overexpressing tumors.

Keyphrases

pet imaging
cell therapy
emergency department
computed tomography
drug induced